Literature DB >> 10793082

Expression of the ALK tyrosine kinase gene in neuroblastoma.

L Lamant1, K Pulford, D Bischof, S W Morris, D Y Mason, G Delsol, B Mariamé.   

Abstract

ALK (anaplastic lymphoma kinase) is a tyrosine kinase receptor, expressed as part of the chimeric NPM-ALK protein, in anaplastic large cell lymphomas (ALCLs) exhibiting the t(2;5)(p23;q35) translocation. As a result of this translocation, the NPM (nucleophosmin) gene is fused to the portion of the ALK gene encoding its intracytoplasmic segment. In normal mouse tissues, mRNA encoding the Alk receptor has been found only in neural cells, suggesting involvement of this receptor in the development of the nervous system. The purpose of the present study was to examine the presence of ALK transcripts and protein in normal human tissues and a variety of cell lines and human tumors. Emphasis was placed on neuroblastomas because other tyrosine kinase receptors are expressed in human neuroblastomas. Fifty-six cell lines, including 29 lines of neural origin, and lymphoid and nonlymphoid tissue specimens, including 24 neuroblastomas, were investigated for ALK expression, using reverse transcriptase-polymerase chain reaction, Western blotting, and immunohistochemistry. The results confirmed that mRNA encoding ALK protein was not detectable in any normal or neoplastic hematopoietic tissue tested, except for t(2;5)-positive ALCL. The salient finding was that 13 of the 29 cell lines of neural origin and 22 of 24 neuroblastomas were found to express ALK transcripts and ALK protein. However, no correlation was evident between any known prognostic factors and the level of ALK expression.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10793082      PMCID: PMC1876934          DOI: 10.1016/S0002-9440(10)65042-0

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  26 in total

1.  ALK expression defines a distinct group of T/null lymphomas ("ALK lymphomas") with a wide morphological spectrum.

Authors:  B Falini; B Bigerna; M Fizzotti; K Pulford; S A Pileri; G Delsol; A Carbone; M Paulli; U Magrini; F Menestrina; R Giardini; S Pilotti; A Mezzelani; B Ugolini; M Billi; A Pucciarini; R Pacini; P G Pelicci; L Flenghi
Journal:  Am J Pathol       Date:  1998-09       Impact factor: 4.307

2.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.

Authors:  M M Bradford
Journal:  Anal Biochem       Date:  1976-05-07       Impact factor: 3.365

3.  Major nucleolar proteins shuttle between nucleus and cytoplasm.

Authors:  R A Borer; C F Lehner; H M Eppenberger; E A Nigg
Journal:  Cell       Date:  1989-02-10       Impact factor: 41.582

4.  Nucleolar localization of the nucleophosmin-anaplastic lymphoma kinase is not required for malignant transformation.

Authors:  D Y Mason; K A Pulford; D Bischof; M U Kuefer; L H Butler; L Lamant; G Delsol; S W Morris
Journal:  Cancer Res       Date:  1998-03-01       Impact factor: 12.701

5.  Alterations in the PITSLRE protein kinase gene complex on chromosome 1p36 in childhood neuroblastoma.

Authors:  J M Lahti; M Valentine; J Xiang; B Jones; J Amann; J Grenet; G Richmond; A T Look; V J Kidd
Journal:  Nat Genet       Date:  1994-07       Impact factor: 38.330

6.  Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma.

Authors:  S W Morris; M N Kirstein; M B Valentine; K G Dittmer; D N Shapiro; D L Saltman; A T Look
Journal:  Science       Date:  1994-03-04       Impact factor: 47.728

7.  Inverse relationship between trk expression and N-myc amplification in human neuroblastomas.

Authors:  A Nakagawara; M Arima; C G Azar; N J Scavarda; G M Brodeur
Journal:  Cancer Res       Date:  1992-03-01       Impact factor: 12.701

Review 8.  A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group.

Authors:  N L Harris; E S Jaffe; H Stein; P M Banks; J K Chan; M L Cleary; G Delsol; C De Wolf-Peeters; B Falini; K C Gatter
Journal:  Blood       Date:  1994-09-01       Impact factor: 22.113

9.  Expression of trkA cDNA in neuroblastomas mediates differentiation in vitro and in vivo.

Authors:  H Matsushima; E Bogenmann
Journal:  Mol Cell Biol       Date:  1993-12       Impact factor: 4.272

10.  trk and ret proto-oncogene expression in human neuroblastoma specimens: high frequency of trk expression in non-advanced stages.

Authors:  M G Borrello; I Bongarzone; M A Pierotti; R Luksch; M Gasparini; P Collini; S Pilotti; M G Rizzetti; P Mondellini; B De Bernardi
Journal:  Int J Cancer       Date:  1993-06-19       Impact factor: 7.396

View more
  57 in total

Review 1.  Emerging importance of ALK in neuroblastoma.

Authors:  Anna M Azarova; Gargi Gautam; Rani E George
Journal:  Semin Cancer Biol       Date:  2011-09-16       Impact factor: 15.707

2.  Functional validation of the anaplastic lymphoma kinase signature identifies CEBPB and BCL2A1 as critical target genes.

Authors:  Roberto Piva; Elisa Pellegrino; Michela Mattioli; Luca Agnelli; Luigia Lombardi; Francesco Boccalatte; Giulia Costa; Bruce A Ruggeri; Mangeng Cheng; Roberto Chiarle; Giorgio Palestro; Antonino Neri; Giorgio Inghirami
Journal:  J Clin Invest       Date:  2006-11-16       Impact factor: 14.808

Review 3.  Pathobiology of ALK+ anaplastic large-cell lymphoma.

Authors:  Hesham M Amin; Raymond Lai
Journal:  Blood       Date:  2007-05-22       Impact factor: 22.113

4.  Targeting ALK in pediatric RMS does not induce antitumor activity in vivo.

Authors:  Monika Wierdl; Lyudmila Tsurkan; Liying Chi; M Jason Hatfield; Viktor Tollemar; Cori Bradley; Xiang Chen; Chunxu Qu; Philip M Potter
Journal:  Cancer Chemother Pharmacol       Date:  2018-05-31       Impact factor: 3.333

5.  Proteolysis Targeting Chimeras (PROTACs) of Anaplastic Lymphoma Kinase (ALK).

Authors:  Chengwei Zhang; Xiao-Ran Han; Xiaobao Yang; Biao Jiang; Jing Liu; Yue Xiong; Jian Jin
Journal:  Eur J Med Chem       Date:  2018-03-27       Impact factor: 6.514

Review 6.  Cell survival signaling in neuroblastoma.

Authors:  Michael L Megison; Lauren A Gillory; Elizabeth A Beierle
Journal:  Anticancer Agents Med Chem       Date:  2013-05       Impact factor: 2.505

Review 7.  ALK-immunoreactive neoplasms.

Authors:  Parham Minoo; Huan-You Wang
Journal:  Int J Clin Exp Pathol       Date:  2012-05-23

Review 8.  Anaplastic lymphoma kinase: role in cancer pathogenesis and small-molecule inhibitor development for therapy.

Authors:  Thomas R Webb; Jake Slavish; Rani E George; A Thomas Look; Liquan Xue; Qin Jiang; Xiaoli Cui; Walter B Rentrop; Stephan W Morris
Journal:  Expert Rev Anticancer Ther       Date:  2009-03       Impact factor: 4.512

9.  Anaplastic lymphoma kinase is expressed in different subtypes of human breast cancer.

Authors:  Pablo Perez-Pinera; Y Chang; A Astudillo; J Mortimer; T F Deuel
Journal:  Biochem Biophys Res Commun       Date:  2007-04-30       Impact factor: 3.575

Review 10.  Anaplastic lymphoma kinase: signalling in development and disease.

Authors:  Ruth H Palmer; Emma Vernersson; Caroline Grabbe; Bengt Hallberg
Journal:  Biochem J       Date:  2009-05-27       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.